Related Experiment Video
Updated: Mar 24, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.8K
Liraglutide for treating type 1 diabetes.
Thomas Fremming Dejgaard1,2, Christian Seerup Frandsen1, Jens Juul Holst3,4
1a Department of Endocrinology, Hvidovre Hospital , University of Copenhagen , Hvidovre , Denmark.
Expert Opinion on Biological Therapy
|March 2, 2016
Summary
Liraglutide, a type 1 diabetes treatment, did not consistently improve glycemic control when added to insulin. While it reduced weight and insulin dosage, its use is not recommended for improving HbA1c levels.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 1 diabetes management often fails to meet glycemic targets.
- New therapeutic strategies complementing insulin are needed.
- Liraglutide, a GLP-1 receptor agonist, is explored as an adjunct therapy.
Purpose of the Study:
- To review the mechanism of action, efficacy, and safety of liraglutide as an add-on to insulin in type 1 diabetes.
- To evaluate liraglutide's potential role in managing type 1 diabetes.
Main Methods:
- Systematic review of physiological and clinical data.
- Searches conducted in Cochrane library, MEDLINE, and EMBASE databases.
- Data analysis focused on liraglutide's impact on glycemic control, weight, insulin dosage, and adverse events.
Main Results:
- Liraglutide adjunct therapy reduced body weight and daily insulin dose compared to insulin alone.
- HbA1c improvements were inconsistent, with small studies showing benefits but placebo-controlled trials showing no significant clinical effect.
- Adverse events were primarily transient gastrointestinal issues, notably nausea.
Conclusions:
- Current data does not support liraglutide as an add-on therapy to insulin for improving glycemic control in type 1 diabetes.
- Ongoing trials may clarify liraglutide's future role, particularly in newly diagnosed or insulin pump-treated patients.
- Further research is needed to determine the definitive place of liraglutide in type 1 diabetes management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
929
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
929
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
998
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
998
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
918
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
918
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
845
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
845